Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/76004
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sur, D. | - |
dc.contributor.author | Kanungo, S. | - |
dc.contributor.author | Sah, B. | - |
dc.contributor.author | Manna, B. | - |
dc.contributor.author | Ali, M. | - |
dc.contributor.author | Paisley, A.M. | - |
dc.contributor.author | Niyogi, S.K. | - |
dc.contributor.author | Park, J.K. | - |
dc.contributor.author | Sarkar, B. | - |
dc.contributor.author | Puri, M.K. | - |
dc.contributor.author | Kim, D.R. | - |
dc.contributor.author | Deen, J.L. | - |
dc.contributor.author | Holmgren, J. | - |
dc.contributor.author | Carbis, R. | - |
dc.contributor.author | Rao, R. | - |
dc.contributor.author | Thu Van, N. | - |
dc.contributor.author | Han, S.H. | - |
dc.contributor.author | Attridge, S. | - |
dc.contributor.author | Donner, A. | - |
dc.contributor.author | Ganguly, N.K. | - |
dc.contributor.author | et al. | - |
dc.contributor.editor | Ryan, E.T. | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | PLoS Neglected Tropical Diseases, 2011; 5(10):e1289-1-e1289-6 | - |
dc.identifier.issn | 1935-2735 | - |
dc.identifier.issn | 1935-2735 | - |
dc.identifier.uri | http://hdl.handle.net/2440/76004 | - |
dc.description.abstract | BACKGROUND: Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical trials. METHODS/PRINCIPAL FINDINGS: We conducted a cluster-randomized, placebo-controlled trial of a two-dose regimen of a low-cost killed whole cell OCV in residents 1 year of age and older living in 3,933 clusters in Kolkata, India. The primary endpoint was culture-proven Vibrio cholerae O1 diarrhea episodes severe enough to require treatment in a health care facility. Of the 66,900 fully dosed individuals (31,932 vaccinees and 34,968 placebo recipients), 38 vaccinees and 128 placebo-recipients developed cholera during three years of follow-up (protective efficacy 66%; one-sided 95%CI lower bound = 53%, p<0.001). Vaccine protection during the third year of follow-up was 65% (one-sided 95%CI lower bound = 44%, p<0.001). Significant protection was evident in the second year of follow-up in children vaccinated at ages 1–4 years and in the third year in older age groups. CONCLUSIONS/SIGNIFICANCE: The killed whole-cell OCV conferred significant protection that was evident in the second year of follow-up in young children and was sustained for at least three years in older age groups. Continued follow-up will be important to establish the vaccine's duration of protection. | - |
dc.description.statementofresponsibility | Dipika Sur ... Stephen Attridge ... et al. | - |
dc.language.iso | en | - |
dc.publisher | Public Library of Science | - |
dc.rights | © 2011 Sur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | - |
dc.source.uri | http://dx.doi.org/10.1371/journal.pntd.0001289 | - |
dc.title | Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1371/journal.pntd.0001289 | - |
pubs.publication-status | Published | - |
Appears in Collections: | Aurora harvest 7 Molecular and Biomedical Science publications |
Files in This Item:
File | Size | Format | |
---|---|---|---|
hdl_76004.pdf | 445.41 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.